Möchten Sie immer auf dem neuesten Stand bleiben?

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it intends to offer and sell, in an underwritten public offering and...

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...

Market growth is fueled by growing awareness of skin health, technological innovation, and expanding applications in both medical and cosmetic dermatology.

VGTel Announces Provisional Patent Filing and Public Release of MiraLink™ Signal Intelligence Framework

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13,...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the...

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...

Report provides in-depth insights into technological developments, pipeline trends, and global opportunities shaping the future of bispecific antibodies.

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET  Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) --...

PORTOLA VALLEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research in the US, today announced publication of...